On May 31, 2019 Apexian Pharmaceuticals, Inc., a clinical stage drug development company focused on advancing APX3330 for the treatment of diseases mediated by the APE1/Ref-1 protein, reported that it will report clinical data from its clinical study, APX-CLN-0011: A Phase 1 Study of APX3330 in Patients with Advanced Solid Tumors in a poster being presented on June 1 at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago, Illinois (Press release, Apexian Pharmaceuticals, MAY 31, 2019, View Source [SID1234536737]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to presenting data on the use of APX3330 in patients with advanced cancers and to discuss the opportunities for clinical advancement of our selective APE1/Ref-1 inhibitor that these trial data provide," said Dr. Mark Kelley, Chief Scientific Officer of Apexian. "Our study enrolled patients across a range of tumor indications, allowing us to identify molecular signals of activity in response to administration of APX3330 as a single agent."

Dr. Richard Messmann, Chief Medical Officer of Apexian added, "These data have also enabled us to confirm the safety of chronic dosing of APX330 and to begin correlating our clinical findings with the molecular activities mediated by targeting the redox component of the APE1/Ref-1 protein. These findings will guide us through the next steps in the development path for APX3330."